세계의 유방암 액체생검 검사 기기 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 제공 품목별, 순환 바이오마커별, 용도별, 지역별, 경쟁별(2020-2030년)

Breast Cancer Liquid Biopsy Testing Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Offerings, By Circulating Biomarker, By Application, By Region & Competition, 2020-2030F

US $ 4,500 ￦ 6,240,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,627,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,094,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

유방암 액체생검 검사 기기 세계 시장은 2024년 8억 3,536만 달러로 평가되었습니다. 예측 기간 동안 17.20%의 연평균 복합 성장률(CAGR)로 괄목할 만한 성장을 보일 것으로 예상됩니다.

액체생검은 유방암 진단 및 치료 영역에서 귀중한 자산으로 작용할 수 있습니다. 액체생검을 통한 돌연변이 분석은 종양 특이적 유전자 변화를 기반으로 환자 개개인에 맞는 표적 치료법을 찾아내는데 도움을 줍니다. 예를 들어, 전이성 유방암 환자의 경우, HR 양성 종양의 약 40%에서 발견되는 PIK3CA 돌연변이를 검사하면 가장 효과적인 치료법을 결정하는 데 도움이 될 수 있습니다. 예를 들어, 미국암협회(ASC) 보고서 2023에 따르면 유방암은 피부암을 제외하고 미국에서 여성에게 가장 흔한 암입니다. 매년 진단되는 모든 여성 암의 30%를 차지합니다. 유방암의 유병률과 사망률을 낮추기 위해 정부는 진단과 치료에 드는 비용을 환자들에게 지원하는 정책을 시행하고 법률을 도입하고 있습니다. 또한, 세계보건기구(WHO)의 2023년 보고서에 따르면, 유방암은 연간 230만 명 이상의 환자가 진단받고 있으며, 성인에서 가장 발병률이 높은 암입니다. 그러나 유방암 관련 사망의 약 80%는 중저소득 국가에서 발생합니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	8억 3,536만 달러
시장 규모 : 2030년	21억 4,906만 달러
CAGR : 2025-2030년	17.20%
급성장 부문	순환 종양 DNA
최대 시장	북미

시장 성장 촉진요인

암 감지 기술의 발전

주요 시장 이슈

제한된 감도와 특이성

주요 시장 동향

기존 진단법과의 통합

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 유방암 액체생검 검사 기기 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 제공 품목별(어세이 및 시약 키트, 기기)
  • 순환 바이오마커(순환 종양 DNA, 순환 종양 세포, 세포외 소포)
  • 용도별(암 용도, 암 이외 용도)
  • 지역별
  • 기업별(2022)
• 제품 시장 맵
  • 제공별
  • 순환 바이오마커별
  • 용도별
  • 지역별

제6장 북미의 유방암 액체생검 검사 기기 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 유방암 액체생검 검사 기기 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인

제8장 아시아태평양의 유방암 액체생검 검사 기기 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국

제9장 남미의 유방암 액체생검 검사 기기 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 유방암 액체생검 검사 기기 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 인수합병(M&A)
• 제품 출시

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• A Menarini AG
• NeoGenomics Laboratories Inc
• F Hoffmann-La Roche AG
• Myriad Genetics Inc
• QIAGEN NV
• Biocept Inc
• Sysmex Corp
• Fluxion Biosciences Inc
• Thermo Fisher Scientific Inc
• Epic Sciences Inc

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Breast Cancer Liquid Biopsy Testing Devices Market was valued at USD 835.36 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 17.20% through 2030. Liquid biopsy serves as a valuable asset in the realm of breast cancer diagnosis and treatment. The analysis of mutations through liquid biopsy aids in the identification of targeted therapies tailored to individual patients based on their tumor-specific genetic alterations. To illustrate, in the case of patients grappling with metastatic breast cancer, screening for the PIK3CA mutation, which is found in around 40% of HR-positive tumors, assists in determining the most effective treatment path. For instance, according to the American Society of Cancer (ASC) Report 2023, breast cancer remains the most common cancer among women in the United States, excluding skin cancers. It accounts for 30% of all female cancers diagnosed annually. In an effort to reduce the prevalence and mortality rates of breast cancer, the government has implemented policies and introduced laws to support patients with the costs of diagnosis and treatment. Also, according to the World Health Organization 2023 report, more than 2.3 million cases of breast cancer are diagnosed annually, making it the most prevalent cancer among adults. However, approximately 80% of breast cancer-related deaths occur in low- and middle-income countries.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 835.36 Million
Market Size 2030	USD 2149.06 Million
CAGR 2025-2030	17.20%
Fastest Growing Segment	Circulating Tumor DNA
Largest Market	North America

Key Market Drivers

Advancements in Cancer Detection Technology

The landscape of cancer detection and diagnosis is evolving rapidly, and one area of remarkable progress is the development of liquid biopsy testing devices. These devices, which have gained prominence in the healthcare industry, are offering a non-invasive, highly sensitive, and patient-friendly approach to detect and monitor cancer, with breast cancer being a significant focus.

One of the keyways advancements in cancer detection technology are boosting the growth of the global breast cancer liquid biopsy market is by enhancing sensitivity and specificity. Liquid biopsies can now detect minute traces of circulating tumor DNA (ctDNA) or other biomarkers in a patient's bloodstream. This increased sensitivity ensures that even small tumors or minimal residual disease (MRD) can be detected accurately, which was often challenging with traditional diagnostic methods.

Key Market Challenges

Limited Sensitivity and Specificity

While liquid biopsy testing devices have advanced considerably, they may still face challenges related to sensitivity and specificity. Detecting circulating tumor DNA (ctDNA) or other biomarkers in the bloodstream can be challenging, especially for small or early-stage tumors. Improving the sensitivity and specificity of these tests remains a priority for the industry.

Key Market Trends

Integration with Conventional Diagnostics

The trend is moving towards the integration of liquid biopsy testing devices with traditional diagnostic methods. Combining liquid biopsies with imaging and tissue biopsies can provide a more comprehensive understanding of the disease. This integrated approach offers greater diagnostic accuracy and opens up new avenues for treatment decisions.

Key Market Players

• A Menarini AG
• NeoGenomics Laboratories Inc
• F Hoffmann-La Roche AG
• Myriad Genetics Inc
• QIAGEN NV
• Biocept Inc
• Sysmex Corp
• Fluxion Biosciences Inc
• Thermo Fisher Scientific Inc
• Epic Sciences Inc

Report Scope:

In this report, the Global Breast Cancer Liquid Biopsy Testing Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Breast Cancer Liquid Biopsy Testing Devices Market, By Offerings:

• Assay & Reagents Kits
• Instruments

Breast Cancer Liquid Biopsy Testing Devices Market, By Circulating Biomarker:

• Circulating Tumor DNA
• Circulating Tumor Cell
• Extracellular Vesicles

Breast Cancer Liquid Biopsy Testing Devices Market, By Application:

• Cancer Applications
• Non-Cancer Applications

Breast Cancer Liquid Biopsy Testing Devices Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Breast Cancer Liquid Biopsy Testing Devices Market.

Available Customizations:

Global Breast Cancer Liquid Biopsy Testing Devices market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 5.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 5.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Offerings
  • 5.3.2. By Circulating Biomarker
  • 5.3.3. By Application
  • 5.3.4. By Region

6. North America Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 6.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 6.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Offerings
      • 6.3.1.2.2. By Circulating Biomarker
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Offerings
      • 6.3.2.2.2. By Circulating Biomarker
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Offerings
      • 6.3.3.2.2. By Circulating Biomarker
      • 6.3.3.2.3. By Application

7. Europe Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 7.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 7.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Offerings
      • 7.3.1.2.2. By Circulating Biomarker
      • 7.3.1.2.3. By Application
  • 7.3.2. United Kingdom Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Offerings
      • 7.3.2.2.2. By Circulating Biomarker
      • 7.3.2.2.3. By Application
  • 7.3.3. France Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Offerings
      • 7.3.3.2.2. By Circulating Biomarker
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Offerings
      • 7.3.4.2.2. By Circulating Biomarker
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Offerings
      • 7.3.5.2.2. By Circulating Biomarker
      • 7.3.5.2.3. By Application

8. Asia-Pacific Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 8.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 8.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Offerings
      • 8.3.1.2.2. By Circulating Biomarker
      • 8.3.1.2.3. By Application
  • 8.3.2. Japan Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Offerings
      • 8.3.2.2.2. By Circulating Biomarker
      • 8.3.2.2.3. By Application
  • 8.3.3. India Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Offerings
      • 8.3.3.2.2. By Circulating Biomarker
      • 8.3.3.2.3. By Application
  • 8.3.4. Australia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Offerings
      • 8.3.4.2.2. By Circulating Biomarker
      • 8.3.4.2.3. By Application
  • 8.3.5. South Korea Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Offerings
      • 8.3.5.2.2. By Circulating Biomarker
      • 8.3.5.2.3. By Application

9. South America Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 9.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 9.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Offerings
      • 9.3.1.2.2. By Circulating Biomarker
      • 9.3.1.2.3. By Application
  • 9.3.2. Argentina Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Offerings
      • 9.3.2.2.2. By Circulating Biomarker
      • 9.3.2.2.3. By Application
  • 9.3.3. Colombia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Offerings
      • 9.3.3.2.2. By Circulating Biomarker
      • 9.3.3.2.3. By Application

10. Middle East and Africa Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 10.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 10.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Offerings
      • 10.3.1.2.2. By Circulating Biomarker
      • 10.3.1.2.3. By Application
  • 10.3.2. Saudi Arabia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Offerings
      • 10.3.2.2.2. By Circulating Biomarker
      • 10.3.2.2.3. By Application
  • 10.3.3. UAE Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Offerings
      • 10.3.3.2.2. By Circulating Biomarker
      • 10.3.3.2.3. By Application
  • 10.3.4. Kuwait Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Offerings
      • 10.3.4.2.2. By Circulating Biomarker
      • 10.3.4.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. A Menarini AG
• 14.2. NeoGenomics Laboratories Inc
• 14.3. F Hoffmann-La Roche AG
• 14.4. Myriad Genetics Inc
• 14.5. QIAGEN NV
• 14.6. Biocept Inc
• 14.7. Sysmex Corp
• 14.8. Fluxion Biosciences Inc
• 14.9. Thermo Fisher Scientific Inc
• 14.10. Epic Sciences Inc

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료